New First in Class SGLT2 Drugs Hit a Stumbling Block

New First in Class SGLT2 Drugs Hit a Stumbling Block

FDA delays verdict on Astra/Bristol SGLT2 diabetes pill until Jan 28th, the same day they are deciding on the possible approval of Bydureon. See this week’s Item #4.